Basal B cell lines also showed a significant resistance to well-known inhibitors of the cell cycle (irinotecan, taselisib, 5-fluorouracil), drug inducers of cell death (AZD5582, AZD5991) and other receptor tyrosine kinase inhibitors, such as savolitinib which inhibits c-MET to reduce tumour persistence and metastasis [47]. Here, NTRK1 is linked to neoplasm.